
An experimental drug, added to chemotherapy, may benefit women with an aggressive form of breast cancer, suggests an early study offering much-needed good news. The study involved women with “triple-negative” breast cancer, which accounts for about 15% to 20% of breast cancers among U.S. women. It is so called because the cancers lack receptors for… read on > read on >